Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Nab-Paclitaxel +/- Cisplatin in Advanced Urothelial Carcinoma
NCT04211012Phase 2Unknown
- Start
- Nov 2020
- Primary completion
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in urothelial carcinoma (UC). Status: unknown.
02
Drugs
toripalimab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04211012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04211012.